PMID- 23391565
OWN - NLM
STAT- MEDLINE
DCOM- 20130917
LR  - 20151119
IS  - 1421-9832 (Electronic)
IS  - 1018-8665 (Linking)
VI  - 225
IP  - 4
DP  - 2012
TI  - Febrile ulceronecrotic Mucha-Habermann disease: treatment with infliximab and 
      intravenous immunoglobulins and review of the literature.
PG  - 344-8
LID - 10.1159/000346245 [doi]
AB  - Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is a rare subtype of 
      pityriasis lichenoides et varioliformis acuta, characterized by an acute onset of 
      ulceronecrotic papules, rapidly coalescing into large ulcers with necrotic 
      crusts, associated with high fever and severe systemic symptoms. We report a case 
      of a 65-year-old woman with a resistant form of FUMHD successfully treated with a 
      tumor necrosis factor-alpha (TNFalpha) inhibitor (infliximab). After 1 year of treatment, 
      because of the recurrence of lesions and -occurrence of severe sepsis, we decided 
      to change the therapeutic procedure by introducing intravenous immunoglobulin 
      witch induced a spectacular improvement. Only few cases of FUMHD treated with 
      intravenous immunoglobulin have been reported to date. In our case, we describe 
      the first utilization of TNFalpha inhibitors in the treatment of FUMHD: TNFalpha 
      inhibitors may be useful, particularly in resistant cases. Further reports are 
      required to confirm this potential therapeutic option.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
FAU - Meziane, L
AU  - Meziane L
AD  - Department of Dermatology, Amiens University Medical Centre, South Hospital, and 
      University Picardie Jules Verne, Amiens, France. liliameziane@yahoo.fr
FAU - Caudron, A
AU  - Caudron A
FAU - Dhaille, F
AU  - Dhaille F
FAU - Jourdan, M
AU  - Jourdan M
FAU - Dadban, A
AU  - Dadban A
FAU - Lok, C
AU  - Lok C
FAU - Chaby, G
AU  - Chaby G
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20130131
PL  - Switzerland
TA  - Dermatology
JT  - Dermatology (Basel, Switzerland)
JID - 9203244
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - Febrile Ulceronecrotic Mucha-Habermann disease
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Dermatologic Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Herpes Simplex/*drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Infliximab
MH  - Pityriasis Lichenoides/*drug therapy
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2013/02/09 06:00
MHDA- 2013/09/18 06:00
CRDT- 2013/02/09 06:00
PHST- 2012/08/02 00:00 [received]
PHST- 2012/11/26 00:00 [accepted]
PHST- 2013/02/09 06:00 [entrez]
PHST- 2013/02/09 06:00 [pubmed]
PHST- 2013/09/18 06:00 [medline]
AID - 000346245 [pii]
AID - 10.1159/000346245 [doi]
PST - ppublish
SO  - Dermatology. 2012;225(4):344-8. doi: 10.1159/000346245. Epub 2013 Jan 31.